文献速递肝病

多基因风险评分结合临床纤维化评分优化严重肝病风险分层与预测

A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-06-04

该研究基于英国生物银行266,687名参与者的前瞻性队列数据,中位随访9年,评估在临床纤维化评分基础上加入基于PNPLA3、TM6SF2、MBOAT7和GCKR变异的多基因风险评分(PRS-HFC)能否改善严重肝病(SLD)的风险分层与预测。结果显示,在具有代谢危险因素(糖尿病、肥胖、脂肪肝指数≥60)的人群中,PRS-HFC可进一步区分中/高危纤维化评分患者的SLD风险,并提高预测准确性;而在无代谢危险因素者中影响甚微。

要点

  • PRS-HFC可细化临床纤维化评分中/高危人群的严重肝病风险分层。
  • 在糖尿病、肥胖或脂肪肝指数≥60者中,PRS-HFC的预测改善作用更明显。
  • 无代谢危险因素者中,不利遗传背景对风险分层影响很小或无影响。

核心结论

  • 将PRS-HFC与临床纤维化评分整合可改善严重肝病的个体化风险预测,主要适用于有非酒精性脂肪性肝病风险的人群。

研究设计与样本

  • 基于英国生物银行266,687名参与者的前瞻性队列研究,中位随访9年。

主要发现

  • 不利遗传背景(PRS-HFC≥0.396)可进一步区分中/高危纤维化评分患者的严重肝病风险,在具有代谢危险因素者中效应更强。
  • 整合PRS-HFC后,所有纤维化评分的受试者工作特征曲线下面积均有提高(P值约10^-2至10^-4),但天冬氨酸氨基转移酶与血小板比值在整体人群及肥胖者中除外。
  • PRS-HFC提高了中高危临床评分风险等级中严重肝病的诊断准确性和阳性预测值。
  • 无代谢危险因素者中,不利遗传背景对风险分层和预测无影响或影响甚微。

关键数值与推荐

  • PRS-HFC≥0.396定义为不利遗传背景。
  • 脂肪肝指数阳性定义为≥60。
  • 采用的非酒精性脂肪性肝病纤维化评分包括:NFS、FIB-4、APRI、BARD和Forns评分。
  • 严重肝病包括肝硬化、失代偿性肝病、肝细胞癌和/或肝移植。

临床怎么用

  • 对于临床纤维化评分处于中/高危且有代谢危险因素(糖尿病、肥胖、脂肪肝指数≥60)的患者,可考虑结合PRS-HFC进一步细化严重肝病风险分层。
  • 在无代谢危险因素的人群中,不建议依赖PRS-HFC进行风险再分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A polygenic risk score based on well-known genetic variants in PNPLA3, TM6SF2, MBOAT7, and GCKR predicts hepatic fat content (polygenic risk score-hepatic fat content [PRS-HFC]). Here, we hypothesized that the addition of PRS-HFC to clinical fibrosis scores may improve risk stratification and prediction of severe liver disease (SLD). METHODS: We used data from 266,687 individuals in the UK Biobank, evaluating the incidence of cirrhosis, decompensated liver disease, hepatocellular carcinoma, and/or liver transplantation during a median follow-up period of 9 years. Nonalcoholic fatty liver disease fibrosis score, Fibrosis-4, aspartate aminotransferase-to-platelet ratio, BARD, and Forns scores, and PRS-HFC, were computed. All analyses were stratified according to the presence of diabetes, obesity, and a positive fatty liver index (≥60). RESULTS: Unfavorable genetics (PRS-HFC, ≥0.396) further stratified the risk of SLD in subjects in intermediate-/high-risk classes of fibrosis scores, with a higher effect in those with metabolic risk factors, and the prediction was improved by integrating PRS-HFC (areas under the receiver operating characteristic increased for all scores with a P value of approximately 10-2 to 10-4, except for the aspartate aminotransferase-to-platelet ratio in the overall population and in subjects with obesity). PRS-HFC improved diagnostic accuracies and positive predictive values for SLD in intermediate-high clinical score risk classes. Risk stratification and prediction were not affected or were poorly affected by unfavorable genetics in subjects without metabolic risk factors. CONCLUSIONS: Integration of genetics with clinical fibrosis scores refines individual risk and prediction for SLD, mainly in individuals at risk for nonalcoholic fatty liver disease. These data provide evidence from a prospective cohort that common genetic variants capture additional prognostic insights not conveyed by validated clinical/biochemical parameters.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. De Vincentis A, Tavaglione F, Jamialahmadi O, et al. A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. Clin Gastroenterol Hepatol. 2021. PMID: 34091049. doi:10.1016/j.cgh.2021.05.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。